The relationship between obstructive sleep apnea syndrome and apolipoprotein E genetic variants
Ebru Uyrum1, Oner Balbay, Ali Nihat Annakkaya
1Department of Chest Diseases, Akhisar State Hospital, Manisa, Turkey.
Respiration; International Review of Thoracic Diseases
|January 24, 2015
Summary
Genetic factors influence obstructive sleep apnea syndrome (OSAS). Specific apolipoprotein E (APOE) genotypes, particularly APOE2, significantly increase OSAS risk in a high-risk population.
Area of Science:
- Genetics
- Sleep Medicine
- Molecular Biology
Background:
- Obstructive sleep apnea syndrome (OSAS) is recognized to have a significant genetic predisposition.
- Understanding the genetic underpinnings of OSAS is crucial for identifying individuals at higher risk.
Purpose of the Study:
- To investigate the role of apolipoprotein E (APOE) alleles as a potential genetic risk factor in the development of OSAS.
- To determine the association between specific APOE genotypes and the risk of OSAS.
Main Methods:
- A cohort of 73 patients, including 37 males, underwent comprehensive full-night polysomnography.
- Genotyping was performed to evaluate the distribution of apolipoprotein E (APOE) alleles within the study population.
Main Results:
- The APOE3 allele was prevalent (97.3%), with the E3/E3 genotype being the most common (75.3%).
- Individuals possessing at least one APOE2 allele exhibited a significantly higher risk of OSAS (OR = 9.37, p = 0.019).
- APOE4 alleles showed a trend towards increased OSAS risk, though not statistically significant.
Conclusions:
- Specific apolipoprotein E (APOE) genotypes are demonstrably associated with an increased risk of obstructive sleep apnea syndrome (OSAS).
- The presence of APOE2 alleles represents a significant genetic risk factor for OSAS in this population.
More Related Videos
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
1.7K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.5K
Related Concept Videos
01:21Sleep Apnea
846
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
846
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
72
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
166
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
166
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
01:29Pharmacogenomics: Identification of New Drug Targets
98
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98
01:29Alzheimer Disease l: Introduction
2
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
2